AUS
NZ
UK
CA
USA
IND
Highlights
- Viking Therapeutics CEO Brian Lian to present on January 13, 2025, at the J.P. Morgan Healthcare Conference
- The presentation will be available via live webcast for investors and stakeholders
- Viking Therapeutics continues to focus on developing novel therapies for metabolic and endocrine disorders
Viking Therapeutics (NASDAQ:VKTX), a clinical-stage biopharmaceutical company specializing in the development of novel therapies for metabolic and endocrine disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13-16, 2025, in San Francisco. The company's CEO, Dr. Brian Lian, will deliver a corporate presentation on Monday, January 13, 2025, from 1:30 to 2:10 p.m. Pacific time at The Westin St. Francis San Francisco on Union Square.
Key Presentation Details
Dr. Lian will provide an overview of Viking Therapeutics’ innovative research and development efforts aimed at addressing critical unmet needs in the treatment of metabolic and endocrine diseases. The presentation will focus on the company’s pipeline of therapies that target a range of conditions, including obesity, diabetes, and non-alcoholic steatohepatitis (NASH), among others. The event will offer investors, analysts, and healthcare professionals valuable insights into Viking’s strategic direction and future prospects.
For those unable to attend the conference in person, the presentation will be accessible via live webcast through the Viking Therapeutics website in the Investors & Media section under Webcasts. A replay of the presentation will also be available on the company’s website following the conclusion of the event, allowing stakeholders to stay informed on the company’s latest developments.
In addition to the formal presentation, Dr. Lian will engage in one-on-one meetings with investors, analysts, and other key stakeholders during the event, providing further opportunities for in-depth discussions regarding the company’s progress and future plans.
About Viking Therapeutics
As a clinical-stage biopharmaceutical company, Viking Therapeutics focuses on advancing therapies for metabolic and endocrine disorders. The company is dedicated to developing novel treatments for conditions that have high unmet medical needs, with a particular focus on non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes. Viking's pipeline includes several promising drug candidates, and the company continues to make strides in the clinical development of these therapies.
Opportunities for Growth
Viking Therapeutics’ participation in the J.P. Morgan Healthcare Conference presents an opportunity to highlight its ongoing research and clinical development activities to a broad audience. The company’s emphasis on novel metabolic and endocrine disorder therapies positions it as a promising player in a growing sector of the pharmaceutical industry.
With a pipeline of innovative therapies, Viking has the potential to make significant advancements in the treatment of metabolic and endocrine diseases, which are among the most prevalent health concerns worldwide. The company's commitment to addressing these challenges with cutting-edge treatments makes it a company to watch in the coming years.